Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes Meeting Abstract
| Authors: | Attard, G.; Agarwal, N.; Graff, J. N.; Sandhu, S.; Efstathiou, E.; Özgüroğlu, M.; de Santana Gomes, A. J. P.; Vianna, K. C. M.; Luo, H.; Cheng, H. H.; Kim, W.; Varela, C. R.; Schaeffer, D.; Dibaj, S.; Li, S.; Shen, F.; Mundle, S. D.; Olmos, D.; Chi, K. N.; Rathkopf, D.; on behalf of the AMPLITUDE Investigators |
| Abstract Title: | Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-10 |
| Start Page: | LBA5006 |
| Language: | English |
| ACCESSION: | WOS:001511772800001 |
| DOI: | 10.1200/JCO.2025.43.17_suppl.LBA5006 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
